ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Share Price vs Market Cap

<< Previous

Bullboard Posts

Next >>

Post by DavidKingCanadaon Jul 04, 2021 5:40pm

277 Views

Post# 33491005

Share Price vs Market Cap

As we all know the SP is very low compared to other Companies with similair Market Caps. I was lucky enough to get in at .08 and have already made my profit. I will be unloading 200K Shares in December if there is no Revenue. 330 Million Shares. We need to so a Reverse Split and Start receiving Revenue. Hoping for a PR this Month. A was pointless for the comming Investor.

There also seem to be many Members on this Board that do not like PMN and have no faith in the Company. Why post here if you are not Shareholders?

<< Previous

Bullboard Posts

Next >>

Infield Minerals to acquire Kings Canyon Gold Property